Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Purified n-3 Fatty Acids on Serum Fibrosis Markers and Cardiovascular Risk Markers in a Randomized Placebo Controlled Trial in Patients With Non Alcoholic Fatty Liver Disease
Brief Summary: Non alcoholic fatty liver disease (NAFLD) imposes a high and increasing burden on the NHS, yet there is presently no licensed treatment or validated approach to management. NAFLD predisposes to increased risk of type 2 diabetes, increased risk of cardiovascular disease and may progress to chronic irreversible liver disease.

In NAFLD patients, the investigators will test the hypothesis that treatment with long chain n-3 fatty acid supplementation for 18 months favourably influences bio-markers for NAFLD and risk factors for cardiovascular disease and type 2 diabetes.


Options:
A: Arm Label: Vitamin D + fish oil; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: vitamin D3, Drug: omega-3 fatty acids (fish oil) | Arm Label: Vitamin D + fish oil placebo; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: vitamin D3, Dietary Supplement: Fish oil placebo | Arm Label: Vitamin D placebo + fish oil; Type: ACTIVE_COMPARATOR; Interventions: Drug: omega-3 fatty acids (fish oil), Dietary Supplement: Vitamin D3 placebo | Arm Label: Vitamin D placebo + fish oil placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Vitamin D3 placebo, Dietary Supplement: Fish oil placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: vitamin D3; Assigned to Arm(s): Vitamin D + fish oil, Vitamin D + fish oil placebo | Intervention Type: DRUG; Name: omega-3 fatty acids (fish oil); Assigned to Arm(s): Vitamin D + fish oil, Vitamin D placebo + fish oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3 placebo; Assigned to Arm(s): Vitamin D placebo + fish oil, Vitamin D placebo + fish oil placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Fish oil placebo; Assigned to Arm(s): Vitamin D + fish oil placebo, Vitamin D placebo + fish oil placebo
B: Arm Label: Minocycline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Minocycline | Arm Label: Omega-3 fatty acids; Type: ACTIVE_COMPARATOR; Interventions: Drug: Omega-3 fatty acids | Arm Label: Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Minocycline Plus Omega-3 fatty acids; Type: ACTIVE_COMPARATOR; Interventions: Drug: Minocycline Plus Omega-3 fatty acids | Intervention Type: DRUG; Name: Minocycline; Assigned to Arm(s): Minocycline | Intervention Type: DRUG; Name: Omega-3 fatty acids; Assigned to Arm(s): Omega-3 fatty acids | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Minocycline Plus Omega-3 fatty acids; Assigned to Arm(s): Minocycline Plus Omega-3 fatty acids
C: Arm Label: Omega 3 fatty acid (fish oil); Type: ACTIVE_COMPARATOR; Interventions: Drug: OMACOR | Arm Label: dummy pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo oral capsule | Intervention Type: DRUG; Name: OMACOR; Assigned to Arm(s): Omega 3 fatty acid (fish oil) | Intervention Type: DRUG; Name: Placebo oral capsule; Assigned to Arm(s): dummy pill
D: Intervention Type: DRUG; Name: Epanova™ (Omega-3 Free Fatty Acids); Assigned to Arm(s): N/A

Answer: C